These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 18596600

  • 1. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.
    Olevsky OM, Martino S.
    Menopause; 2008; 15(4 Suppl):790-6. PubMed ID: 18596600
    [Abstract] [Full Text] [Related]

  • 2. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB.
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [Abstract] [Full Text] [Related]

  • 3. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL, Chao HT, Cheng MH, Wang PH.
    Maturitas; 2008 Jun 20; 60(2):92-107. PubMed ID: 18534794
    [Abstract] [Full Text] [Related]

  • 4. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.
    Clin Cancer Res; 2006 Sep 01; 12(17):5242-7. PubMed ID: 16951244
    [Abstract] [Full Text] [Related]

  • 5. [Raloxifene in postmenopausal women].
    Trémollières F, Ribot C.
    Gynecol Obstet Fertil; 2006 Feb 01; 34(2):147-53. PubMed ID: 16483822
    [Abstract] [Full Text] [Related]

  • 6. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG.
    Clin Cancer Res; 2001 Dec 01; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [Abstract] [Full Text] [Related]

  • 7. Chemoprevention in postmenopausal women.
    Rastogi P.
    Menopause; 2008 Dec 01; 15(4 Suppl):810-5. PubMed ID: 18596603
    [Abstract] [Full Text] [Related]

  • 8. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA, Land SR.
    Menopause; 2008 Dec 01; 15(4 Suppl):797-803. PubMed ID: 18596601
    [Abstract] [Full Text] [Related]

  • 9. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar 01; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 10. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR, Duvernoy CS, Calaf J, Adachi JD, Mershon JL, Dowsett SA, Agnusdei D, Stuenkel CA.
    Menopause; 2009 Mar 01; 16(2):413-21. PubMed ID: 19092711
    [Abstract] [Full Text] [Related]

  • 11. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG.
    Ann N Y Acad Sci; 2006 Nov 01; 1089():127-42. PubMed ID: 17261762
    [Abstract] [Full Text] [Related]

  • 12. Raloxifene and risk for stroke based on the framingham stroke risk score.
    Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D.
    Am J Med; 2009 Aug 01; 122(8):754-61. PubMed ID: 19540454
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Raloxifene and its role in breast cancer prevention.
    Eng-Wong J, Zujewski JA.
    Expert Rev Anticancer Ther; 2004 Aug 01; 4(4):523-32. PubMed ID: 15270657
    [Abstract] [Full Text] [Related]

  • 16. Prevention of breast cancer in high-risk women.
    Kardinal CG, Veith R.
    J La State Med Soc; 1999 Apr 01; 151(4):198-201. PubMed ID: 10234895
    [Abstract] [Full Text] [Related]

  • 17. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May 08; 48(1234):37. PubMed ID: 16685245
    [Abstract] [Full Text] [Related]

  • 18. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK, Ford LG.
    Eur J Cancer Prev; 2007 Jun 08; 16(3):232-42. PubMed ID: 17415094
    [Abstract] [Full Text] [Related]

  • 19. [CORE study].
    Mizunuma H.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():294-8. PubMed ID: 18161121
    [No Abstract] [Full Text] [Related]

  • 20. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H.
    Clin Calcium; 2008 Oct 28; 18(10):1442-50. PubMed ID: 18830041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.